Leonhardt Ventures Unveils Wireless Bioelectric Stent Platform for Regenerative Medicine
TL;DR
Leonhardt Ventures' E-Stent technology offers exclusive licensing opportunities across 29 medical applications, creating first-mover advantages in regenerative medicine markets.
The E-Stent system uses wireless wearable harnesses to deliver bioelectric signals through micro-coils embedded in stents, controlling specific protein expressions for targeted regeneration.
This wireless bioelectric stent platform could significantly improve treatment outcomes for conditions ranging from Alzheimer's to heart disease, potentially enhancing millions of lives worldwide.
Leonhardt Ventures' wireless E-Stent can stimulate proteins like klotho and sirtuins to regenerate organs from brain to pancreas using bioelectric signals.
Found this article helpful?
Share it with your network and spread the knowledge!
Leonhardt Ventures LLC announced the introduction of E-Stent™, the first wireless bioelectric protein-expression stent designed to activate or inhibit specific regenerative proteins directly from vessel walls and surrounding tissues. The technology platform combines a next-generation implant with a wireless wearable harness that delivers controlled protein expressions to micro-coils embedded along the stent, with sizes ranging from micro-implants smaller than a pea to 28 mm aortic stents.
Brian Lasater, CTO of Leonhardt Ventures LLC and Lionheart Health, Inc., stated that working prototypes are currently in testing and are controlling regenerative and healing protein expressions on demand enabled fully by wireless energy. The company has granted exclusive licenses for the E-Stent™ platform across 29 specialized medical applications to various entities including KidneyCell™ for kidney regeneration, CerebraCell™ for brain health and stroke recovery, and CancerCell™ for cancer treatment.
Other licensed applications include AddictiStim™ for addiction treatment, MemoryStim™ for memory improvement and Alzheimer's treatment, and DepressiStim™ for severe depression and anxiety treatment. The platform also extends to BioLeonhardt™ for heart regeneration, Ear-Cell™ for hearing regeneration, and Eye-Cell™ for vision regeneration.
Through selective bioelectric signaling, the E-Stent™ platform can stimulate or inhibit a broad range of proteins including klotho, sestrins, sirtuins, apelin, and many others known to influence regenerative processes. These stimulations can be directed to control stem cell homing, proliferation, and differentiation on demand, improving circulation, restoring muscle strength, modulating inflammation and blood pressure, improving nerve connections and viability, and restoring elasticity.
The platform represents a significant evolution of Leonhardt Ventures' previously announced KlothoImplant Bioelectric MicroImplant, expanding the same core capabilities into advanced vascular implant formats. The Lionheart Health team, majority owned by Leonhardt Ventures LLC, was recently recognized by Medtech Outlook Magazine as Micro Implant Stimulator Development of the Year 2025. The company was also recognized as Abbvie Allergan ULP Innovation of the Year in Medical Aesthetics and as a top 40 semi-finalist in the $101 Million Xprize Healthspan competition out of 600 entries.
Additional licensed applications include Lionheart Health for healthspan longevity and medical aesthetics, Vascustim™ for peripheral artery disease, AortaCell™ for aortic aneurysm treatment, and SpineStim™ for spinal cord injury recovery. The technology platform also addresses orthopedic applications through OrthoStim™ and dental applications via DentaCell™.
This development marks a potential transformation in regenerative medicine, offering targeted control over protein expressions that could address numerous chronic conditions and degenerative diseases. The wireless nature of the technology and its application across multiple organ systems positions it as a platform technology with broad implications for medical treatment approaches. However, the company notes that products are not fully proven yet to be safe or effective as all are still in clinical studies.
Curated from Newsworthy.ai
